Pediatric medulloblastomas are radiosensitive and mostly curable tumors if they are non-metastasized. Postsurgery adjuvant radiation therapy remains the cornerstone therapy in the curative intent treatment. In case of children less than three years, pre-irradiation chemotherapy is given to defer radiotherapy till the child is three year old. Introduction of conformal radiotherapy in addition to technical improvements in surgery and radiotherapy, risks definition and molecular analysis of prognostic factors has most likely contributed to the improved survival rates. Children should ideally be referred in time to an appropriate higher center with adequate infrastructure, expertise and radiotherapy facilities for better outcome of the disease.